Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 10 → 14 locations
  2. Study sites: 8 to 10 Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 4 of 16 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 16 entries
  3. Trial sites expanded: 5 → 8 locationsv4
  4. Study sites: 3 to 5 Start date changed from estimate of Sep 11, 2026 to Aug 27, 2026v3 Show 1 more changeShow less
    • Start date changed from estimate of Sep 11, 2026 to Aug 27, 2026
  5. Recruitment opened Trial sites expanded: 0 → 3 locationsv2 Show 1 more changeShow less
    • Trial sites expanded: 0 → 3 locations
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.
Trial Details
NCT Number NCT07768371
Lead Sponsor Novartis Pharmaceuticals
Conditions IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Enrollment 576 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov